News ArticleGland Pharma Releases Unaudited Consolidated Results for Q2 and H1 September 2026 with Auditor Reviews of Subsidiaries
Board approves financial statements reflecting total assets and revenues from group entities including subsidiaries reported by Deloitte and other auditors
Gland Pharma Limited announced its unaudited consolidated financial results for the quarter and half year ended September 30, 2026, including review reports from Deloitte Haskins & Sells and other auditors for subsidiaries. The results comply with Indian Accounting Standards and reflect total assets, revenues, and losses from key subsidiaries as disclosed.
Gland Pharma Limited
Financial Results
Gland Pharma Limited announced its unaudited consolidated financial results for the quarter and half year ended September 30, 2026, with audit reviews completed by Deloitte Haskins & Sells and other auditors for its subsidiaries.
The Board of Directors approved the standalone and consolidated unaudited financial results prepared under Indian Accounting Standards, pursuant to SEBI Listing Regulations.
The consolidated results include the financial information of the holding company and nine subsidiaries across India, Singapore, USA, France, and Belgium.
Deloitte Haskins & Sells reviewed the consolidated results in accordance with applicable Indian auditing standards and issued an unmodified conclusion on the statements.
Two subsidiaries with total assets of ₹3,750.03 million, revenues of ₹1,194.22 million for the quarter and ₹2,848.76 million for the half year, and losses after tax of ₹333.37 million (quarter) and ₹250.93 million (half year) were reviewed by other auditors.
Two additional subsidiaries, not audited, reported total assets of ₹36.59 million with net losses after tax of ₹1.32 million (quarter) and ₹3.10 million (half year). Their interim results were considered immaterial by management and auditors alike.
Highlights
- Board meeting held on November 6, 2026, approved Q2 and H1 financial results.
- Consolidated results encompass 1 holding company and 9 subsidiaries internationally.
- Review performed by Deloitte and other auditors under SEBI Regulation 33.
- Subsidiaries reported combined total assets of over ₹3,786 million as of September 30, 2026.
- Subsidiaries showed total revenues of more than ₹2,848 million for the half year period.
- Net losses recorded in some subsidiaries impacting consolidated results but considered non-material overall.
Key Data Snapshot
What happened
- Gland Pharma's Board approved unaudited standalone and consolidated financial results for Q2 and H1 September 2026.
- The financial results were prepared in compliance with Indian Accounting Standards and SEBI Listing Regulations.
- The results include the performance of the holding company and its subsidiaries internationally.
Key details
- Deloitte Haskins & Sells performed the independent auditor’s review of the consolidated financials.
- The review included operations of Gland Pharma Limited and subsidiaries in Singapore, USA, France, and Belgium.
- Two subsidiaries with significant total assets and revenues were reviewed by other auditors.
- Two other subsidiaries were unaudited and reported immaterial financial figures.
Regulatory and governance context
- Results filed under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), 2015.
- Deloitte reviewed in accordance with Standard on Review Engagement (SRE) 2410 issued by ICAI.
- Interim financial statements comply with Ind AS 34 for interim reporting.
Background and context
- Gland Pharma Limited operates through various subsidiaries globally.
- The consolidated results combine financial information from the parent and eight wholly-owned subsidiaries.
- Subsidiaries contribute materially to consolidated assets and revenues, with some reporting losses.
Highlights
- Board meeting held on November 6, 2026, approved Q2 and H1 financial results.
- Consolidated results encompass 1 holding company and 9 subsidiaries internationally.
- Review performed by Deloitte and other auditors under SEBI Regulation 33.
- Subsidiaries reported combined total assets of over ₹3,786 million as of September 30, 2026.
- Subsidiaries showed total revenues of more than ₹2,848 million for the half year period.
- Net losses recorded in some subsidiaries impacting consolidated results but considered non-material overall.
Disclosures
- SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
- Indian Accounting Standard 34 - Interim Financial Reporting
Source Information
More News on Financial Results
View allLatest corporate announcements and market updates in Financial Results.
Pradeep Metals Releases Q2 and H1 FY2027 Unaudited Financial Results and Updates Defence Facility Progress
Pradeep Metals Limited announced its unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. The company also updated stakeholders on its new Defence Manufacturing Facility located at Butibori, Nagpur.
Read Full Story
SAL Steel Reports Unaudited Financial Results for Q2 and H1 FY2027 with Total Revenue of Rs. 231.27 Crore
SAL Steel Limited announced its unaudited standalone financial results for the quarter and half year ended September 30, 2026, reporting total revenue of Rs. 231.27 crore for the half year. The company also disclosed key balance sheet figures and announced the resignation of Independent Woman Director Nipa Jairaj Shah, effective November 6, 2026.
Read Full Story
Indo Borax & Chemicals Limited Reports Rs. 13,624.64 Lakh Income and Acquisition of Kronox Lab Sciences in H1 FY2026
Indo Borax & Chemicals Limited approved its un-audited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. Key highlights include acquisition of a controlling stake in Kronox Lab Sciences Limited and a net profit of Rs. 2,772.25 lakh in the first half of the fiscal year.
Read Full Story
